GSK strikes up to $750 million deal for cancer-targeting drug - Reuters
GSK strikes up to $750 million deal for cancer-targeting drug Reuters
Coverage by Political Leaning
See how different sides of the spectrum reported this story
All Coverage
<a href="https://news.google.com/rss/articles/CBMirgFBVV95cUxQcjJidHNYWUF0VXZIQ203SXAtTHBFNVE4dk1EVkJCWTRMcHZRMktYTmZ4SU5lemhGWUpabi1yMFhkQ1pIYjdMZWFWLTJkVnNkRXZIa2FnZW1rQjZCQVVsLVVEOHdTRlFyYzVfSTNCMzFERGk4RWVLR01va3FNdUxHRzNCcktKWk5jaUtLMnRzVTgwR3ByamFPOGJmVmxvQWd6QVkzMFRpRWZlSlQxM2c?oc=5" target="_blank">GSK strikes up to $750 million deal for cancer-targeting drug</a> <font color="#6f6f6f">Reuters</font>
Similar Stories
Related coverage based on topic and tags
US FDA advisers endorse Grail cancer test's benefits in key vote - Reuters
US FDA advisers endorse Grail cancer test's benefits in key vote Reuters
September 23, 2026 at 11:03 PMChina's InnoCare, Eli Lilly sign collaboration deal worth up to $3.35 billion - Reuters
China's InnoCare, Eli Lilly sign collaboration deal worth up to $3.35 billion Reuters
September 24, 2026 at 04:55 AMRNA drug developer ADARx seeks $1.74 billion valuation in US IPO - Reuters
RNA drug developer ADARx seeks $1.74 billion valuation in US IPO Reuters
September 21, 2026 at 11:43 AMAI-based drug developer Basecamp valued at $800 million after $140 million funding round - Reuters
AI-based drug developer Basecamp valued at $800 million after $140 million funding round Reuters
September 23, 2026 at 01:08 PMMerck's drug for diabetes-related eye disease meets trial goal - Reuters
Merck's drug for diabetes-related eye disease meets trial goal Reuters
September 24, 2026 at 02:52 PMUS FDA approves AbbVie's drug for Parkinson's disease - reuters.com
US FDA approves AbbVie's drug for Parkinson's disease reuters.com
September 25, 2026 at 10:57 PM